EUROAPI Shares Fall 8.77% Over the Week Despite Favorable Sector Context
The stock of the active pharmaceutical ingredient manufacturer closed on Friday at €3.036, down 8.77% over the week. This decline occurred even though the European pharmaceutical sector experienced a positive momentum at the start of the period, driven by favorable announcements from the United States regarding drug pricing policies.
Weekly Stock Performance
The week began at €3.298 on Monday before marking a first decline on Tuesday to €3.238. A technical rebound on Wednesday, accompanied by the highest volume of the week with 165,334 shares traded, brought the price back to €3.294. However, this recovery did not hold: the stock suffered a significant drop on Thursday to €3.15 and continued its descent on Friday. Throughout the period, trading volumes remained moderate, ranging between 62,000 and 165,000 shares per session. This downward movement is much more pronounced than that of the benchmark indices, with both the CAC 40 and the SBF 120 having declined by about 1.7% over the same period.
Sector Context in Early October
The sector context at the beginning of October makes this performance all the more notable. European pharmaceutical stocks, including heavyweights like Roche, AstraZeneca, and Sanofi, posted significant gains early in the week following the announcement by the Trump administration of the launch of a site for purchasing drugs at reduced prices and an agreement with Pfizer. These developments, considered reassuring for the industry, propelled some sector stocks by more than 5%. EUROAPI, however, did not benefit from this momentum. Additionally, the company recently adjusted its forecasts for 2025, now anticipating a moderate decline in revenue rather than stabilization, while maintaining its EBITDA margin target between 7 and 9%.
